Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 14/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828305 | 0.85 | S1PR5 (0.40) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL1828277 | 0.82 | ALDH1A1 (0.46) | — | |
| SCHEMBL1831069 | 0.80 | L3MBTL1 (0.39) | S1PR5POLB | |
| SCHEMBL883931 | 0.78 | MAPT (0.47) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL883930 | 0.78 | S1PR5 (0.38) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL4678480 | 0.77 | POLB (0.53) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL13905850 | 0.73 | S1PR5 (0.42) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL30479891 | 0.73 | POLB (0.42) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL29226681 | 0.73 | S1PR5 (0.38) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL1362777 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735387-B2 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| CN-102159582-B | Oxazolopyrimidines as edg-1 receptor agonists | SANOFI AVENTIS | 2014-05-07 | — | — | CN | disclosed |
| EP-2583720-A1 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2013-04-24 | — | — | EP | disclosed |
| CN-102159582-A | Oxazolopyrimidines as edg-1 receptor agonists | SANOFI AVENTIS | 2011-08-17 | — | — | CN | disclosed |
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-2318415-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010006704-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | EDNRA, OXGR1, EDF1 | S1PR5 85/4885S1PR1 49/4885POLB 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.